Salacia for Blood Sugar
Salacia is a genus of plants whose roots, stems and leaves have been used against diabetes in Asia for hundreds of years, in Ayurvedic medicine and by traditional physicians in Sri Lanka and India. Three species appear in the research: Salacia reticulata, a woody climber known in Sri Lanka as Kothala himbutu, Salacia oblonga and Salacia chinensis. The plants contain unusual sulfur-bearing sugars, chiefly salacinol and kotalanol, which in laboratory tests slow the gut enzymes that cut starch and table sugar into glucose.
State of the evidence: modest and short-term. Seven reports of randomized trials of a single Salacia species are among the records reviewed for this page. Those that compared Salacia with placebo or a control meal reported a smaller rise in blood sugar or insulin after a test meal, or a lower hemoglobin A1C (HbA1c) after weeks to months of daily use. Where the abstracts give figures, the differences are modest: in a trial of 136 people with type 2 diabetes, HbA1c was 0.25% lower than with placebo. The trials are small, they used different species and preparations, none tested Salacia alone in place of diabetes medication, and a 2015 review concluded that a larger evidence base from well-planned studies is required to confirm efficacy and safety.
Table of Contents
What the Plant Is and How It Has Been Used
The Salacia plants belong to the family Celastraceae; older papers place them in the family Hippocrateaceae. A review by the research group that isolated the main active compounds names three species as its sources, Salacia reticulata, Salacia oblonga and Salacia chinensis, and states that their roots and stems have been used in Ayurvedic medicine as a specific remedy at the early stage of diabetes (PMID 33900535).
Extracts of the roots, stems and leaves of Salacia reticulata have been used in Asia for hundreds of years as a folk treatment for diabetes (PMID 26031882). The plant is a woody climber, used widely in the Ayurvedic system to treat diabetes and obesity. The review that describes it notes that nearly 50% of people with diabetes worldwide use complementary medicines to treat their diabetes or to add to their conventional treatment (PMID 25889885). A 2008 review states that Salacia roots have also been consumed extensively in Japan, the United States and other countries as a food supplement (PMID 18433791).
Three Species, Studied Separately
The research does not treat Salacia as one plant. Each trial used one species, and the species are not chemically equal. A laboratory analysis measured salacinol and kotalanol in extracts of the three species and of four plant parts (roots, stems, leaves and fruits). The extract from the roots of Salacia reticulata had the highest content of both compounds (PMID 20303690). For this reason every study on this page is reported with the species it used.
Active Compounds and How They Act
Starch and table sugar (sucrose) cannot pass from the gut into the blood as they are. Starch is a chain of glucose units and sucrose is a pair of sugar units. Enzymes on the lining of the small intestine, called alpha-glucosidases, cut them into single sugars such as glucose, and only the single sugars are absorbed. Maltase, sucrase and isomaltase are enzymes of this group.
When these enzymes are slowed, carbohydrate is digested over a longer time and glucose reaches the blood more slowly after a meal. The prescription drug acarbose acts at this step. That is the reason most Salacia trials measure the rise in blood sugar after a meal or a sugar drink.
The Salacia compounds studied most are salacinol and kotalanol. They are thiosugars, sugars in which a sulfur atom takes the place of an oxygen atom. Kotalanol was isolated from the roots and stems of Salacia reticulata and described as a potent alpha-glucosidase inhibitor on the strength of laboratory enzyme tests (PMID 9734318). Reviews list further compounds of the same family (neokotalanol, ponkorinol, salaprinol and forms that lack a sulfate group), and also mangiferin, kotalagenin 16-acetate and several proanthocyanidins (PMID 33900535, PMID 26031882).
Other Proposed Actions
Reviews describe Salacia extracts as acting on several targets besides alpha-glucosidase: aldose reductase (an enzyme linked to diabetic complications), pancreatic lipase (a fat-digesting enzyme), a receptor that controls fat-handling genes (peroxisome proliferator-activated receptor alpha), glucose uptake through the glucose transporter 4, and the angiotensin II type 1 receptor (PMID 26031882, PMID 18433791). These reviews draw on laboratory and rodent work as well as human studies, and their abstracts do not say which of these actions has been shown in people.
One human trial measured a gut hormone. In adults with prediabetes who took a standardized Salacia reticulata extract for 12 weeks, total glucagon-like peptide-1, a gut hormone that raises insulin release after eating, differed significantly between the extract and placebo groups. The abstract does not give the direction or size of the difference (PMID 42663504).
What Human Trials Found
Single-meal trials give Salacia once, with a test meal or sugar drink, and follow blood sugar and insulin for a few hours. Longer trials give it daily and measure HbA1c, the blood test that reflects average blood sugar over roughly the previous three months, reported as a percentage. A placebo is a look-alike preparation with no active ingredient. In a crossover trial each person takes every treatment in turn. The area under the curve is a single figure for how high blood sugar or insulin rose and how long it stayed up after a meal.
| Species and preparation | People studied | Comparison and length | Result in the abstract |
|---|---|---|---|
| Salacia reticulata standardized extract | 100 adults with prediabetes | 500 mg a day against placebo, 12 weeks | Lower fasting and post-meal glucose, HbA1c and triglycerides; no figures for size |
| Salacia reticulata herbal tea | 51 people with type 2 diabetes | Tea against placebo tea, 3 months each, crossover | HbA1c 6.29 after the tea, 6.65 after placebo |
| Salacia reticulata extract in a biscuit | 136 people with type 2 diabetes | Biscuit against placebo biscuit, crossover | HbA1c 0.25% lower than with placebo |
| Salacia oblonga extract | 66 people with type 2 diabetes | 240 mg or 480 mg with one test meal against the meal alone, crossover | Glucose area under the curve 14% and 22% lower |
| Salacia chinensis extract | Not stated in the abstract | Single doses of 150, 300 or 600 mg against placebo; then 600 mg a day, 12 weeks | Dose-dependent lowering of post-meal glucose and insulin; improved HbA1c; no figures |
| Salacia chinensis extract | 35 healthy volunteers | Single doses of 200, 300 or 500 mg with a sucrose drink against placebo, crossover | Insulin area under the curve significantly lower; no glucose result |
Salacia Reticulata Extract in Prediabetes
A randomized, double-blind, placebo-controlled trial enrolled 100 adults with prediabetes, defined in the trial as a fasting plasma glucose of 100–139 mg/dL together with a post-meal plasma glucose of 140–199 mg/dL. Fifty received a standardized Salacia reticulata extract, 500 mg a day, and fifty received placebo, for 12 weeks.
Compared with placebo, the extract significantly reduced fasting plasma glucose and post-meal plasma glucose (the abstract names the 90-minute and 120-minute readings). During an oral glucose tolerance test, in which a person drinks a measured amount of glucose and blood is sampled over two hours, the glucose areas under the curve for 0–30, 0–60, 0–90 and 0–120 minutes were significantly lower in the extract group. HbA1c and triglycerides were significantly reduced, and 1,5-anhydroglucitol, a blood marker that falls when blood sugar runs high, was significantly increased. All are reported as P below .05; the abstract gives no figures for the size of any change (PMID 42663504).
Salacia Reticulata Tea in Type 2 Diabetes
A randomized, double-blind crossover trial at a single centre studied 51 people who had had type 2 diabetes for longer than 6 months, with stable control over the preceding 6 months. They drank a standard preparation of a herbal tea containing Salacia reticulata for 3 months and a placebo tea in similar tea bags for 3 months, 28 in that order and 23 in the reverse order. All received detailed advice on diet, exercise and lifestyle, and all completed both periods.
HbA1c was 6.29 (standard deviation 1.02) at the end of the tea period and 6.65 (standard deviation 1.04) at the end of the placebo period (P = 0.008). The abstract reports a fall in HbA1c of 0.54 (standard deviation 0.93) with the tea against a rise of 0.3 (standard deviation 1.05) with placebo (P < 0.001).
The participants were taking diabetes medication, so this trial tested the tea added to usual treatment. The mean daily dose of glibenclamide, a sulfonylurea drug, fell by 1.89 mg in the tea period and rose by 2.25 mg in the placebo period. With P = 0.07, that difference did not reach statistical significance, and the differences in metformin dose were not significant either (PMID 15707755). The trial did not show that the tea reduced the need for medication.
Salacia Reticulata Biscuit in Type 2 Diabetes
A trial described by its authors as triple-blind, randomized, placebo-controlled and crossover tested a biscuit containing Salacia reticulata extract, eaten as a snack, against an identical placebo biscuit. Of 230 patients screened, 136 were randomized. People with severe kidney, liver or heart disease were excluded, and patients who came to need insulin were withdrawn. The primary outcome was HbA1c.
Mean HbA1c at the start was 8.45% in one group and 8.65% in the other. The unadjusted mean HbA1c fell from baseline by 0.10% after the placebo biscuit (95% confidence interval −0.12 to 0.32; P = 0.324, not significant) and by 0.35% after the Salacia biscuit (95% confidence interval 0.10 to 0.60; P = 0.003). HbA1c was 8.46% after the placebo biscuit and 8.19% after the Salacia biscuit. The authors concluded that the biscuit reduces HbA1c by 0.25% compared with placebo, without serious kidney or liver adverse effects (PMID 37885536).
Salacia Oblonga Extract With a Single Meal
A randomized, double-blinded crossover trial at several centres studied 66 people with type 2 diabetes. After fasting, each consumed a standard high-carbohydrate liquid meal alone, the meal with 240 mg of Salacia oblonga extract, and the meal with 480 mg. Blood was sampled for up to 180 minutes.
Compared with the meal alone, the glucose area under the curve was 14% lower with 240 mg and 22% lower with 480 mg, and the adjusted peak glucose response was 19% and 27% lower. The insulin area under the curve was 14% and 19% lower, and the adjusted peak insulin response 9% and 12% lower (PMID 17616771). This trial measured one meal. It does not show what daily use does to HbA1c.
A second Salacia oblonga report cannot show what Salacia does. In a double-blind, randomized study of 41 adults aged 40 to 69 with raised fasting glucose or raised blood fats, one group drank for 60 days a tea combining Salacia with a lipopolysaccharide from a bacterium that lives in association with wheat, and the control group took Salacia without it. The combined tea lowered fasting glucose and HbA1c more rapidly than the control in the raised-blood-fat group (PMID 22125681). Both groups took Salacia, so the result concerns the additive.
Salacia Chinensis Extract
One paper reports two randomized, double-blind, placebo-controlled studies. The first was a single-dose crossover study of 150, 300 or 600 mg of Salacia chinensis extract or placebo, with at least 6 days between test days. The extract produced a significant, dose-dependent suppression of post-meal blood glucose and insulin and of their incremental areas under the curve; the 600 mg dose appeared to have the most significant effect. The second was a 12-week parallel-group study of 600 mg a day, in which the extract significantly improved several blood glucose measures, including HbA1c and glucose tolerance after a glucose challenge. The abstract gives neither the number of participants nor the size of the changes (PMID 33370165). The journal later published a correction to this paper; the correction has no abstract in PubMed, so what was corrected cannot be stated here (PMID 33739888).
In a placebo-controlled randomized crossover study, 35 healthy volunteers took 200 mg, 300 mg or 500 mg of Salacia chinensis extract, or placebo, with a sucrose solution, and blood was sampled from 0 to 180 minutes. The insulin area under the curve was significantly lower after the extract. The title of the paper states that glucose response improved, but the abstract reports no glucose result (PMID 27803937).
Multi-Herb Products That Contain Salacia
Two reports tested Salacia mixed with other plants. Neither can show what Salacia contributed. In a study indexed as a randomized controlled trial, 89 people with type 2 diabetes took 1000 mg a day of a five-plant combination that included Salacia oblonga for 8 weeks. Fasting and post-meal blood glucose were significantly lower after 8 weeks, and glycosylated hemoglobin and blood fats improved. The abstract does not describe a placebo group, and the authors called for longer study in larger populations (PMID 24976431).
A randomized, double-blind trial compared a formulation of six plant extracts, one of them Salacia reticulata, plus piperine from black pepper, with metformin for 120 days. It enrolled 29 people with prediabetes (12 on metformin, 17 on the formulation) and 40 with newly diagnosed diabetes (16 on metformin, 24 on the formulation). HbA1c, fasting blood sugar and post-meal blood sugar changed significantly with the formulation in both kinds of patient. The results were comparable to metformin, except that post-meal blood sugar fell significantly more with the formulation in the newly diagnosed group (P = 0.026). No adverse events were reported (PMID 34789340). The trial was small, had no placebo group and tested a seven-ingredient mixture. No record reviewed for this page compared Salacia on its own with a diabetes drug.
What the Reviews Concluded
A 2015 review of Salacia reticulata found animal studies and clinical trials consistent in showing improved glucose levels, both fasting and after sucrose and maltose loads, and reported clinically significant reductions of HbA1c and plasma insulin with 6 weeks to 3 months of treatment. Its last sentence is that a larger evidence base from well-planned studies is required to confirm efficacy and safety (PMID 25889885). A second 2015 review states that in human studies Salacia extracts decreased plasma glucose, insulin and HbA1c with no adverse effects being reported (PMID 26031882).
A 2026 review of plant compounds that act on post-meal blood sugar names mulberry preparations and Salacia extracts as the strongest examples of a path from known chemistry to clinical trials, including randomized trials that reduced post-meal glucose or HbA1c. The same review states that short-term effects do not establish durable benefit, and that a candidate needs defined chemistry and human testing of the specific product (PMID 42943244).
What Animal and Laboratory Studies Found
Everything in this section comes from enzyme tests, insects, rodents or cultured cells. None of it is a finding in people.
Enzyme tests. In the laboratory work that first described kotalanol, the compound showed more potent inhibitory activity against sucrase, the enzyme that splits table sugar, than salacinol and than the drug acarbose (PMID 9734318). A later laboratory study isolated a third compound from a water extract of Salacia reticulata, a ring-shaped sulfoxide with 13 atoms in the ring. Its strength was measured as the concentration that cuts an enzyme's activity by half; a lower figure means a stronger blocker. The figures were 0.227 micromolar for maltase, 0.186 micromolar for sucrase and 0.099 micromolar for isomaltase, which the authors describe as much greater activity than that of salacinol and kotalanol (PMID 18547114).
A 2026 review states that potency in a laboratory test alone is insufficient: the composition of the meal, the source of the enzyme, the concentration reached inside the gut and the standardization of the product all bear on whether a laboratory result carries over to people (PMID 42943244).
Silkworms. In silkworms, insects used as a simple screening system, an extract of Salacia reticulata suppressed the rise in sugar level caused by feeding sucrose. Giving the extract together with a lactic acid bacterium had a stronger effect than either one alone (PMID 31327788).
Mice and rats. In mice bred as a model of type 2 diabetes, the tea that combined Salacia with a bacterial lipopolysaccharide significantly decreased plasma glucose (PMID 22125681). In diabetic rats, the five-plant combination that includes Salacia oblonga gave protection similar to that reported in the patients of the same paper (PMID 24976431). Both are findings for mixtures. A 2015 review reports that in the belly fat of mice, Salacia reticulata raised the activity of the genes for hormone-sensitive lipase, an enzyme that releases stored fat, and for adiponectin, a hormone made by fat cells (PMID 25889885).
Weight and toxicity in rodents. Weight loss and smaller weight gain have been shown in animal models, while no clinical study had examined weight loss in people. The same review describes extracts of the three Salacia species as exceedingly safe in rats and mice (PMID 26031882).
Amounts Used in the Trials
These are the amounts the researchers gave. They describe the trials; they are not doses for a reader. Each belongs to one species and one preparation.
- Salacia reticulata standardized extract: 500 mg a day for 12 weeks.
- Salacia reticulata tea: a standard preparation in tea bags for 3 months; the abstract gives no weight of plant material.
- Salacia reticulata biscuit: eaten as a snack; the abstract gives no amount of extract.
- Salacia oblonga extract: 240 mg or 480 mg once, with a high-carbohydrate liquid meal.
- Salacia chinensis extract: single doses of 150 to 600 mg, in one study with a sucrose drink, and 600 mg a day for 12 weeks.
- Mixtures: 1000 mg a day of a five-plant combination for 8 weeks; a seven-ingredient formulation twice a day for 120 days, with no amount in the abstract.
Two single-dose trials gave Salacia together with the test meal or the sugar drink, which fits a compound that acts on digestion inside the gut. A 2015 review states that the large number of active compounds makes it difficult to establish standards for Salacia extracts (PMID 26031882). A milligram figure from one extract therefore says little about another.
Safety Findings and Interactions
What the trials reported. The trial abstracts report few problems. The 12-week trial of Salacia reticulata extract in prediabetes observed no clinically meaningful safety concerns (PMID 42663504). The single-dose study of Salacia chinensis in healthy volunteers observed no significant adverse events (PMID 27803937). The biscuit trial reported no serious kidney or liver adverse effects; it excluded people with severe kidney, liver or heart disease, so its findings do not cover them (PMID 37885536). The tea trial checked liver and kidney blood tests at the start and at 3 and 6 months, and its authors concluded that the tea was safe (PMID 15707755).
What is not known. The trials were small and short, so rare or slow-developing harm would not have been seen. A 2008 review states that toxicology studies in rodents suggested minimal adverse effects, that a clinical trial is crucial to confirm the safety of Salacia roots, and that further study is necessary to understand how Salacia root may interact with other treatments (PMID 18433791). None of the abstracts reviewed for this page mentions pregnancy or breastfeeding.
Gas and loose stools. Drugs that block alpha-glucosidase, such as acarbose, are known for intestinal gas, bloating and loose stools: carbohydrate that is not digested in the small intestine passes to the large intestine, where bacteria ferment it. The Salacia compounds act at the same step, but the abstracts reviewed for this page do not report these effects. A 2026 review lists gastrointestinal tolerance among the factors that decide whether a plant enzyme blocker is useful in practice (PMID 42943244).
Low blood sugar and diabetes medication. Herbs that lower blood sugar add to the effect of insulin and of sulfonylurea drugs, which can themselves push blood sugar too low (hypoglycemia). The signs of low blood sugar are shakiness, sweating, a fast heartbeat and confusion, and at lower levels seizure or loss of consciousness. In the tea trial the participants were taking glibenclamide, a sulfonylurea, and metformin; its abstract does not report how often low blood sugar occurred. In the biscuit trial, patients who needed insulin were withdrawn, so that trial gives no information on Salacia taken together with insulin.
Table sugar during low blood sugar. With acarbose, table sugar corrects low blood sugar slowly, because the drug blocks the enzyme that splits table sugar; pure glucose needs no splitting and is not held back. Kotalanol blocked that same enzyme, sucrase, in a laboratory test (PMID 9734318). No record reviewed for this page tested whether Salacia slows the effect of table sugar in a person with low blood sugar.
Type 1 diabetes. Type 1 diabetes is a state of absolute insulin deficiency. No herb, food or diet replaces insulin; without insulin, diabetic ketoacidosis develops, and it is fatal if untreated. No trial abstract reviewed for this page mentions type 1 diabetes.
Products differ. Herbal products vary in plant part, extract and content from one product to the next, so a trial result for one preparation does not transfer to another. For Salacia this has been measured: the content of salacinol and kotalanol differed between the three species and between roots, stems, leaves and fruits (PMID 20303690).
Limits of the Evidence
- Small and short trials. The trials that state their size enrolled 35 to 136 people. Those that state a length ran for one meal, 12 weeks, or 3 months per treatment. None followed complications of diabetes such as eye, kidney or nerve damage.
- Modest size of effect. In the biscuit trial HbA1c was 0.25% lower than with placebo and stood at 8.19% after the Salacia period.
- Missing figures. Several abstracts report significant results without stating how large they were, and one does not state how many people took part.
- Different species and preparations. Extracts, a tea and a biscuit from three species were tested. No record compares one species or preparation with another in people.
- No test of Salacia in place of medication. In the tea trial the changes in glibenclamide and metformin doses were not statistically significant. The only comparison with metformin used a seven-ingredient mixture.
- Mechanism shown in the laboratory. The enzyme-blocking action rests on laboratory tests. The human trials measured blood sugar, insulin and HbA1c, which fit that mechanism without proving it.
- The reviews ask for more. A 2015 review calls for a larger evidence base from well-planned studies, and a 2026 review states that short-term effects do not establish durable benefit.
Key Research Papers
- Baek HI, Gwon Y, Park SJ. Attenuation of Fasting and Postprandial Glucose Exposure by Standardized Salacia reticulata Extract in Adults with Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. J Med Food. 2026;29(12):734-746. PubMed PMID: 42663504
- Jayawardena MH, de Alwis NM, Hettigoda V, Fernando DJ. A double blind randomised placebo controlled cross over study of a herbal preparation containing Salacia reticulata in the treatment of type 2 diabetes. J Ethnopharmacol. 2005;97(2):215-8. PubMed PMID: 15707755
- Siribaddana S, Medagama A, Wickramasinghe N, Siribaddana NM, Agampodi S, Fernando D. The Effect of Salacia Reticulata Extract Biscuits on Blood Sugar Control of Type 2 Diabetes Mellitus Patients: A Two-Period, Two-Sequence, Crossover, Randomized, Triple-Blind, Placebo-Controlled, Clinical Trial. Cureus. 2023;15(9):e45921. PubMed PMID: 37885536
- Williams JA, Choe YS, Noss MJ, Baumgartner CJ, Mustad VA. Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes. Am J Clin Nutr. 2007;86(1):124-30. PubMed PMID: 17616771
- Nakata K, Taniguchi Y, Yoshioka N, Yoshida A, Inagawa H, Nakamoto T, et al. A mixture of Salacia oblonga extract and IP-PA1 reduces fasting plasma glucose (FPG) and low-density lipoprotein (LDL) cholesterol levels. Nutr Res Pract. 2011;5(5):435-42. PubMed PMID: 22125681
- Kobayashi M, Akaki J, Ninomiya K, Yoshikawa M, Muraoka O, Morikawa T, et al. Dose-Dependent Suppression of Postprandial Hyperglycemia and Improvement of Blood Glucose Parameters by Salacia chinensis Extract: Two Randomized, Double-Blind, Placebo-Controlled Studies. J Med Food. 2021;24(1):10-17. PubMed PMID: 33370165
- Correction to: Dose-Dependent Suppression of Postprandial Hyperglycemia and Improvement of Blood Glucose Parameters by Salacia chinensis Extract: Two Randomized, Double-Blind, Placebo-Controlled Studies, by Kobayashi M, et al. Journal of Medicinal Food 2021; 24(1):10-17;DOI: 10.1089/jmf.2020.4751. J Med Food. 2021;24(3):331. PubMed PMID: 33739888
- Jeykodi S, Deshpande J, Juturu V. Salacia Extract Improves Postprandial Glucose and Insulin Response: A Randomized Double-Blind, Placebo Controlled, Crossover Study in Healthy Volunteers. J Diabetes Res. 2016;2016:7971831. PubMed PMID: 27803937
- Kurian GA, Manjusha V, Nair SS, Varghese T, Padikkala J. Short-term effect of G-400, polyherbal formulation in the management of hyperglycemia and hyperlipidemia conditions in patients with type 2 diabetes mellitus. Nutrition. 2014;30(10):1158-64. PubMed PMID: 24976431
- Majeed M, Majeed A, Nagabhusahnam K, Mundkur L, Paulose S. A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin. Diabetol Metab Syndr. 2021;13(1):132. PubMed PMID: 34789340
- Medagama AB. Salacia reticulata (Kothala himbutu) revisited; a missed opportunity to treat diabetes and obesity? Nutr J. 2015;14:21. PubMed PMID: 25889885
- Stohs SJ, Ray S. Anti-diabetic and Anti-hyperlipidemic Effects and Safety of Salacia reticulata and Related Species. Phytother Res. 2015;29(7):986-95. PubMed PMID: 26031882
- Li Y, Huang TH, Yamahara J. Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity. Life Sci. 2008;82(21-22):1045-9. PubMed PMID: 18433791
- Morikawa T, Ninomiya K, Tanabe G, Matsuda H, Yoshikawa M, Muraoka O. A review of antidiabetic active thiosugar sulfoniums, salacinol and neokotalanol, from plants of the genus Salacia. J Nat Med. 2021;75(3):449-466. PubMed PMID: 33900535
- Vasilica PDF, Trasca DM, Kamal AM, Varut RM, Popa R, Dorin PI, et al. Plant-Derived Control of Postprandial Glycemia: α-Amylase, α-Glucosidase, and the Incretin-DPP-4 Interface. Pharmaceuticals (Basel). 2026;19(10):1546. PubMed PMID: 42943244
- Yoshikawa M, Murakami T, Yashiro K, Matsuda H. Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata. Chem Pharm Bull (Tokyo). 1998;46(8):1339-40. PubMed PMID: 9734318
- Ozaki S, Oe H, Kitamura S. Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008;71(6):981-4. PubMed PMID: 18547114
- Muraoka O, Morikawa T, Miyake S, Akaki J, Ninomiya K, Yoshikawa M. Quantitative determination of potent alpha-glucosidase inhibitors, salacinol and kotalanol, in Salacia species using liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2010;52(5):770-3. PubMed PMID: 20303690
- Ishii M, Matsumoto Y, Katada T, Sekimizu K. Additive effects of Kothala himbutu (Salacia reticulata) extract and a lactic acid bacterium (Enterococcus faecalis YM0831) for suppression of sucrose-induced hyperglycemia in an in vivo silkworm evaluation system. Drug Discov Ther. 2019;13(3):133-136. PubMed PMID: 31327788